Breaking Finance News

Zacks Investment Research announced Revance Therapeutics Inc (NASDAQ:RVNC), bumping its price target to $17.00 earlier today

Only yesterday Revance Therapeutics Inc (NASDAQ:RVNC) traded 2.79% higher at $15.94. Revance Therapeutics Inc’s 50-day average is $15.29 and its two hundred day moving average is $16.15. The last closing price is down -2.01% relative to the two hundred day moving average, compared to the S&P 500 which has decreased -0.01% over the same period. Volume of trade was down over the average, with 103,269 shares of RVNC changing hands under the typical 203,028

Zacks Investment Research raised the target price of Revance Therapeutics Inc (NASDAQ:RVNC) to $17.00 reporting a possible upside of 0.07%.

Performance Chart

Revance Therapeutics Inc (NASDAQ:RVNC)

Revance Therapeutics Inc has with a 52 week low of $12.54 and a one year high of $42.41 and has a total market value of $0.

In addition to Zacks Investment Research reporting its target price, a total of 6 firms have issued a report on the company. The average stock price target is $51.33 with three brokerages rating the company a strong buy, two analysts rating the stock a buy, 0 brokers rating the company a hold, zero firms rating the stock a underperform, and finally 0 analysts rating the company a sell.

Brief Synopsis About Revance Therapeutics Inc (NASDAQ:RVNC)

Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *